Difference between revisions of "Levoleucovorin (Fusilev)"
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Folic acid analog that is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid (racemic d,l [[Folinic acid (Leucovorin)]]). Counteracts the effects of folic acid antagonists such as methotrexate, which acts by inhibiting dihydrofolate reductase. Enhances the activity of [[Fluorouracil (5-FU)]] by inhibiting thymidylate synthase.<ref name="insert">[http:// | + | Class/mechanism: Folic acid analog that is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid (racemic d,l [[Folinic acid (Leucovorin)]]). Counteracts the effects of folic acid antagonists such as [[Methotrexate (MTX) | methotrexate]], which acts by inhibiting dihydrofolate reductase. Enhances the activity of [[Fluorouracil (5-FU)]] by inhibiting thymidylate synthase.<ref name="insert">[http://fusilev.com/downloads/m1-14-1-3-1125-000503-clean.pdf Levoleucovorin (Fusilev) package insert]</ref><ref>[[Media:Levoleucovorin.pdf | Levoleucovorin (Fusilev) package insert (locally hosted backup)]]</ref><ref>[http://fusilev.com/ Fusilev manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 8: | Line 8: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/levoleucovorin-patient-drug-information Levoleucovorin (Fusilev) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/levoleucovorin-patient-drug-information Levoleucovorin (Fusilev) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/levoleucovorin-patient-drug-information Levoleucovorin (Fusilev) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/levoleucovorin-patient-drug-information Levoleucovorin (Fusilev) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *3/7/2008: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020140lbl.pdf FDA approved] "to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists." "Levoleucovorin rescue is indicated after high-dose methotrexate therapy in [[Bone cancer | osteosarcoma]]." | ||
| + | |||
| + | ==Also known as== | ||
| + | Levoleucovorin calcium | ||
==References== | ==References== | ||
Revision as of 06:25, 24 January 2015
General information
Class/mechanism: Folic acid analog that is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid (racemic d,l Folinic acid (Leucovorin)). Counteracts the effects of folic acid antagonists such as methotrexate, which acts by inhibiting dihydrofolate reductase. Enhances the activity of Fluorouracil (5-FU) by inhibiting thymidylate synthase.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 3/7/2008: FDA approved "to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists." "Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma."
Also known as
Levoleucovorin calcium